Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Remune in HIV-Infected Subjects on HAART or HAART + IL-2
NCT00000943Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of Remune in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Lymphocyte proliferative responses to HIV antigens at Week 24. Status: completed.
02
Drugs
Remune
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000943.